Innovent Begins Dosing in Phase I Study of IBI3002 in Australia

Innovent Biologics, a premier biopharmaceutical firm specializing in the development of high-quality therapeutics for a range of diseases including cancer, metabolic disorders, and autoimmune conditions, has initiated a phase 1 clinical trial for IBI3002 in Australia. This novel bispecific antibody is designed to target both the Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP), marking a first in the global pharmaceutical industry. The clinical trial, identified by the registry number NCT06213844, is a randomized, double-blind, and placebo-controlled study that focuses on the safety, tolerability, pharmacokinetics, and pharmacodynamics of IBI3002 in both healthy individuals and those with mild to moderate asthma. The findings will aid in the continued global clinical development of this innovative treatment.
IBI3002 represents a significant advancement in the treatment of inflammatory diseases, particularly asthma, by effectively blocking both IL-4Rα and TSLP, which are pivotal in the pathogenesis of type 2 (T2) inflammatory disorders. The humanized bispecific antibody has demonstrated superior performance in in-vitro assays compared to existing monoclonal antibodies, suggesting a potential synergistic effect in mitigating T2 inflammation, which could lead to improved management of T2 inflammatory diseases.
Dr. Lei Qian, Innovent's Vice President of Clinical Development, highlighted the transformative impact of biological therapies in asthma treatment, emphasizing the potential for precision medicine and optimal disease control across various severe asthma phenotypes. Asthma, a disease characterized by chronic airway inflammation and variable symptoms, affects an estimated 358 million individuals worldwide. It is further categorized into eosinophilic and non-eosinophilic types, with the latter being less understood. Severe asthma, which affects a significant proportion of patients, requires additional treatment options, such as biologic therapies, to manage the disease burden effectively.
Innovent, established in 2011, is dedicated to making high-quality biologics accessible to all. With a robust pipeline that includes 10 marketed products, 3 new drug applications under review, and 4 assets in Phase III or pivotal trials, the company is at the forefront of biopharmaceutical innovation. Collaborating with over 30 global healthcare leaders, Innovent is committed to advancing the industry and ensuring that top-tier pharmaceuticals are widely available. The company operates under a principle of integrity and action, striving to maintain the highest standards in the industry.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!